145 related articles for article (PubMed ID: 30645679)
1. Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
Pediatr Nephrol; 2019 Apr; 34(4):741-742. PubMed ID: 30645679
[TBL] [Abstract][Full Text] [Related]
2. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab in children with hemolytic uremic syndrome.
Kavanagh D; Smith-Jackson K
Kidney Int; 2016 Mar; 89(3):537-8. PubMed ID: 26880449
[TBL] [Abstract][Full Text] [Related]
4. Erratum to: Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse.
Henstridge CM; Jackson RJ; Kim JM; Herrmann AG; Wright AK; Harris SE; Bastin ME; Starr JM; Wardlaw J; Gillingwater TH; Smith C; McKenzie CA; Cox SR; Deary IJ; Spires-Jones TL
Acta Neuropathol Commun; 2015 Dec; 3(1):83. PubMed ID: 26651483
[TBL] [Abstract][Full Text] [Related]
5. Atypical hemolytic uremic syndrome: a new drug program and first Polish adult patient treated with eculizumab.
Ruszkowski J; Heleniak Z; Dębska-Ślizień A
Pol Merkur Lekarski; 2018 Sep; 45(267):119-121. PubMed ID: 30240381
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab.
Vakiti A; Singh D; Pilla R; Alhaj-Moustafa M; Fitzpatrick KW
J Oncol Pharm Pract; 2019 Jun; 25(4):1011-1015. PubMed ID: 29768958
[TBL] [Abstract][Full Text] [Related]
7. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
[TBL] [Abstract][Full Text] [Related]
8. Correction to: The Isolation and Characterization of Kronos, a Novel Caulobacter Rhizosphere Phage that is Similar to Lambdoid Phages.
Berrios L; Ely B
Curr Microbiol; 2019 Aug; 76(8):964-965. PubMed ID: 31030269
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report].
Reis S; Ramos D; Cordinhã C; Gomes C
Acta Med Port; 2019 Oct; 32(10):673-675. PubMed ID: 31625881
[TBL] [Abstract][Full Text] [Related]
11. Correction to: Axially aligned electrically conducting biodegradable nanofibers for neural regeneration.
Subramanian A; Krishnan UM; Sethuraman S
J Mater Sci Mater Med; 2019 May; 30(5):56. PubMed ID: 31087155
[TBL] [Abstract][Full Text] [Related]
12. Correction to: State-Level Variation in Vocational Rehabilitation Service Use and Related Outcomes Among Transition-Age Youth on the Autism Spectrum.
Roux AM; Rast JE; Shattuck PT
J Autism Dev Disord; 2020 Jul; 50(7):2462-2463. PubMed ID: 30949878
[TBL] [Abstract][Full Text] [Related]
13. Correction to: Point estimate and reference normality interval of MRI-derived myocardial extracellular volume in healthy subjects: a systematic review and meta-analysis.
Sardanelli F; Schiaffino S; Zanardo M; Secchi F; Cannaò PM; Ambrogi F; Di Leo G
Eur Radiol; 2019 Dec; 29(12):7076-7077. PubMed ID: 31278579
[TBL] [Abstract][Full Text] [Related]
14. A Case of
Rasa M; Musgrave J; Abe K; Tanaka L; Xoinis K; Shiramizu B; Foskett G; Lau R
J Investig Med High Impact Case Rep; 2017; 5(4):2324709617741144. PubMed ID: 29152520
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.
Wijnsma KL; Duineveld C; Volokhina EB; van den Heuvel LP; van de Kar NCAJ; Wetzels JFM
Nephrol Dial Transplant; 2018 Apr; 33(4):635-645. PubMed ID: 29106598
[TBL] [Abstract][Full Text] [Related]
16. Correction to: Epicardial fat volume measured on nongated chest CT is a predictor of coronary artery disease.
Nagayama Y; Nakamura N; Itatani R; Oda S; Kusunoki S; Takahashi H; Nakaura T; Utsunomiya D; Yamashita Y
Eur Radiol; 2019 Dec; 29(12):7078-7079. PubMed ID: 31278578
[TBL] [Abstract][Full Text] [Related]
17. [Ocular thrombotic microangiopathy in atypical hemolytic-uremic syndrome (a clinical case study)].
Smirnova TV; Sheludchenko VM; Kozlovskaya NL; Kazaryan EE; Andzhelova DV; Sherstneva LV; Velieva IA; Kuchieva AM; Akaeva MI
Vestn Oftalmol; 2018; 134(5. Vyp. 2):215-226. PubMed ID: 30499520
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
[TBL] [Abstract][Full Text] [Related]
20. C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.
Kerboua KE; Haiba F; Batouche D
J Immunoassay Immunochem; 2017; 38(2):178-189. PubMed ID: 27617501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
